Low-Dose DOACs Reduce VTE Risk in Transplant-Ineligible Multiple Myeloma: Insights from the BENEFIT Trial
Journal of Thrombosis and Haemostasis (JTH) has shared a post on LinkedIn:
“Thromboembolism in transplant-ineligible multiple myeloma patients on triplet/quadruplet therapy: a post hoc analysis of the BENEFIT trial
In this phase 3 trial of 257 patients with transplant-ineligible newly diagnosed multiple myeloma, the 6-month cumulative incidence of VTE was 4.8%. Among prophylaxis strategies, low-dose DOACs significantly reduced VTE risk compared to heparin or aspirin. Proteinuria ≥0.44 g/L and monoclonal protein ≥22 g/L emerged as strong independent risk factors for VTE. Findings highlight DOACs as a potentially superior prophylaxis option in this high-risk population.”
Title: Thromboembolism in transplant-ineligible multiple myeloma patients on triplet/quadruplet therapy: a post hoc analysis of BENEFIT trial
Authors: Emilie Chalayer, Corinne Frere, Elisabeth Daguenet, Thomas Lecompte, Bernard Tardy, Ilhame Bounouara, Manon Sapet, Arthur Bobin, Stephanie Harel, Olivier Decaux, Karim Belhadj, Cyrille Touzeau, Margaret Macro, Mohamad Mohty, Philippe Moreau, Jill Corre, Hervé Avet–Loiseau, Lionel Karlin, Thierry Facon, Aurore Perrot, Cyrille Hulin, Salomon Manier, Laurent Frenzel, Xavier Leleu
Read the full paper here.
Find similar posts on Hemostasis Today.
-
Sep 2, 2025, 08:51Perioperative Direct Oral Anticoagulant (DOAC) Dosing: Insights Dr. Sthanu Subramanian
-
Sep 2, 2025, 08:49Why Polycythemia Vera Doesn’t Raise EPO Levels Explained by William Aird
-
Sep 2, 2025, 08:47SUGAR Trial in Heart BMJ: Stent Outcomes in Patients With Diabetes Under the Spotlight
-
Sep 2, 2025, 08:43Eltrombopag with Immunosuppressive Therapy Shows Promising Safety in Pediatric Severe Aplastic Anemia – Phase 2 ESCALATE Trial Results
-
Sep 2, 2025, 08:14Mirvat Alasnag Discusses OPTION-STEMI Findings Published in The Lancet
-
Sep 1, 2025, 15:31Low-Dose DOACs Reduce VTE Risk in Transplant-Ineligible Multiple Myeloma: Insights from the BENEFIT Trial
-
Sep 1, 2025, 07:39Flora Peyvandi: Reappraising Hemostasis Testing in Cirrhosis
-
Sep 1, 2025, 07:35Dario Bongiovanni Presents Milestone Discovery on Reticulated Platelets at ESC Congress 2025
-
Sep 1, 2025, 07:19Felice Gragnano: Clopidogrel vs Aspirin for Secondary Prevention in Coronary Artery Disease – Meta-Analysis Shows Superior MACCE Protection
-
Sep 1, 2025, 07:18Wolfgang Miesbach: New Research Reveals Clonogenic Hepatocytes as the Key Drivers of Liver Growth and Gene Therapy Success
-
Aug 29, 2025, 09:03Vasculearn Network: New 2025 High Blood Pressure Guidelines Are Here
-
Aug 18, 2025, 23:56Dr. Arun V. J Invites You to His Lecture on ‘AI and Data Sciences in Transfusion Medicine’ at the AI in Healthcare Conclave. Register now!
-
Aug 18, 2025, 23:50Safe and Efficient Thrombectomy with Artix System: Clinical Insights from Neil Desai and Colleagues
-
Aug 16, 2025, 14:42Mark Crowther Honors Davide Matino for Leading Promising Hemophilia Trial at McMaster University
-
Aug 14, 2025, 10:28Impressive 95% Clot Removal in a VTE Case: Symphony16F and Symphony24F Catheters
-
Sep 1, 2025, 08:09Wafik S. El-Deiry Opens Up on Recovery, Gratitude, and Book After Life-Changing Heart Surgery
-
Aug 31, 2025, 07:30Michael Albert: Being ‘Metabolically Healthy’ Doesn’t Eliminate Heart Disease Risk
-
Aug 31, 2025, 07:15Should 12-Month DAPT Be the Default After ACS? Mattia Galli Applauds Marco Valgimigli’s Talk
-
Aug 31, 2025, 07:10Ewa Fiorentino-Rozek on Blood Group Genotyping: Are We Ready for Routine Use?
-
Aug 30, 2025, 14:45Gordon’s Journey: 60 Years of Life After DVT Managed with Warfarin